5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | NEUTRAL | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 25.67▼ | 25.65▼ | 25.63▲ | 25.57▲ | 24.75▲ |
MA10 | 25.67▼ | 25.62▲ | 25.67▼ | 25.20▲ | 23.90▲ |
MA20 | 25.65▼ | 25.68▼ | 25.65▼ | 24.72▲ | 24.18▲ |
MA50 | 25.63▲ | 25.64▲ | 25.48▲ | 23.89▲ | 26.12▼ |
MA100 | 25.65▼ | 25.44▲ | 24.87▲ | 24.30▲ | 27.74▼ |
MA200 | 25.67▼ | 24.79▲ | 24.40▲ | 25.65▼ | 37.21▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.001▼ | -0.006▼ | -0.031▼ | 0.099▲ | 0.368▲ |
RSI | 47.535▼ | 49.536▼ | 52.382▲ | 68.101▲ | 55.011▲ |
STOCH | 66.667 | 71.479 | 35.357 | 83.073▲ | 80.783▲ |
WILL %R | -75.000▼ | -45.570 | -65.600 | -17.544▲ | -7.790▲ |
CCI | -40.580 | 59.031 | -37.841 | 77.818 | 170.499▲ |
Friday, July 11, 2025 04:08 AM
Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking Zantac to cancer. Read more here.
|
Thursday, July 10, 2025 11:49 AM
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.
|
Thursday, July 10, 2025 11:49 AM
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
11/07/25 | 25.65 | 25.72 | 25.42 | 25.65 | 34,841,300 |
10/07/25 | 25.58 | 26.05 | 25.54 | 25.78 | 39,480,700 |
09/07/25 | 25.69 | 25.84 | 25.34 | 25.56 | 38,340,800 |
08/07/25 | 25.24 | 25.96 | 25.21 | 25.62 | 51,255,500 |
07/07/25 | 25.36 | 25.53 | 25.14 | 25.24 | 34,896,000 |
03/07/25 | 25.35 | 25.52 | 25.22 | 25.38 | 27,104,600 |
02/07/25 | 25.13 | 25.36 | 25.03 | 25.32 | 36,741,600 |
01/07/25 | 24.28 | 25.35 | 24.26 | 25.04 | 59,120,000 |
30/06/25 | 24.21 | 24.38 | 24.12 | 24.24 | 44,719,700 |
27/06/25 | 24.35 | 24.42 | 24.08 | 24.19 | 39,507,500 |
|
|
||||
|
|
||||
|
|